Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials).
Véronique Crutel, Estelle Lambert, Pierre-François Penelaud and 12 others
PMID 33151500WHAT IT FOUND
No results are reported.
This paper plans two trials of a bumetanide liquid compared with placebo in children and adolescents with moderate to severe autism. The main planned outcome is change in autism symptom scores after six months.
STILL TO COME
How it was doneWhat it means for SLPs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
No results are reported, so the paper cannot show whether bumetanide helps or harms children and adolescents with autism. The studies are described as planned, with an expected 200 patients in each study, so actual enrolment, dropouts, and outcomes are not known. The second 26-week period is open-label, so patients and clinicians will know the treatment during that phase. The main planned outcome is CARS2 change at Week 26; other outcomes, including quality of life and adaptive behaviour, are secondary or exploratory.
The easy way to misread this
Do not read this as evidence that bumetanide improves autism symptoms. No trial results are reported; the paper only describes the planned studies.